Cordis Comes Back for Another Stent

Cordis is getting back into the coronary stent game. The company, which is now owned by Cardinal Health, landed exclusive rights to sell Medinol's coronary stent portfolio in the U.S. Milpitas, CA-based Cordis is already selling Medinol's NIRxcell cobalt-chromium bare-metal stent and, assuming FDA approves Medinol's EluNIR drug-eluting stent (DES), Cordis will distribute it as well. Medinol is based in Israel. In addition to the Medinol agreement, Cordis recently launched the Tryton Side Branch Stent and two percutaneous transluminal coronary angioplasty (PTCA) balloon catheters. The Medinol agreement, along with the availability of the Tryton stent and Meril PTCA balloon catheters, reestablishes Cordis in the U.S. market with a significant interventional cardiology portfolio, said Peter Van Haur, vice president of North America sales and marketing at the company. "By adding these new products to our portfolio, we can make the most significant contribution to the healthcare system and deliver the innovative products and solutions that our customers and their patients are seeking," he said. Cordis used to be one of the biggest players in the coronary stent market under Johnson & Johnson, but J&J decided to quit making stents in 2011. At the time, the company said the decision was due to evolving market dynamics in the drug-eluting stent business, including lower demand, pricing and reimbursement pressure, and a stringent regulatory environment. Dublin, OH-based Car...
Source: MDDI - Category: Medical Devices Authors: Tags: Cardiovascular Source Type: news